Targeting immunogenic cell death for glioma immunotherapy

PMID: 37973489
Journal: Trends in cancer (volume: 10, issue: 1, Trends Cancer 2024 Jan;10(1):8-11)
Published: 2023-11-14

Mishchenko TA, Turubanova VD, Gorshkova EN, Krysko O, Vedunova MV, Krysko DV


Immunogenic cell death (ICD) arouses great interest in targeting glioma, the most common primary brain tumor, to achieve boosted immunotherapy. We discuss the unexpected findings on the induction of Th17 immunity by ICD and propose the best design for dendritic cell (DC)-based vaccines loaded with whole glioma lysates obtained after ICD inducers.